Biocept's book value per share for the quarter that ended in Jun. 2023 was €0.11.
During the past 12 months, Biocept's average Book Value Per Share Growth Rate was -99.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -36.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -41.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Biocept was -30.30% per year. The lowest was -66.10% per year. And the median was -43.50% per year.
Biocept's current price is €6.80. Its book value per share for the quarter that ended in Jun. 2023 was €0.11. Hence, today's PB Ratio of Biocept is 61.26.
During the past 12 years, the highest P/B Ratio of Biocept was 62.79. The lowest was 0.13. And the median was 2.37.
Biocept Book Value per Share Historical Data
The historical data trend for Biocept's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biocept's Book Value per Share
For the Diagnostics & Research subindustry, Biocept's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocept's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biocept's PB Ratio falls into.
Biocept Book Value per Share Calculation
Biocept's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Biocept (FRA:B00) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Biocept Book Value per Share Related Terms
Thank you for viewing the detailed overview of Biocept's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:B00 has been successfully added to your 